PEMBROLIZUMAB

Information current as at: 1 June 2026

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Keytruda
Form and strength:

Please search for and view the meeting agenda from the relevant meeting for more information

Submission sponsor:
Merck Sharp & Dohme (Australia) Pty Ltd
Condition/indication:
(therapeutic use)
  • Advanced and metastatic cancers
Listing requested:
Please see meeting agenda for more information
Funding program:
Please see meeting agenda for more information
Request authority level:
Please see meeting agenda for more information
PBAC Submission type:
Change to listing (–)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
December 2025 PBAC meeting
Opportunity for consumer comment:
--
PBAC meeting:
Held on 10/12/2025
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
22/01/2026
5Lodgement of required documentation:
06/02/2026
Acceptance of complete documentation:
Under consideration
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – December 2025
Case ID
a1194
Page last updated
30 April 2026
Return to the Medicine Status Listing
v.9.19